Thus, our study aimed to evaluate the antimyeloma activity of selinexor in combination with the AURKA inhibitor LY3295668 and to explore the therapeutic relevance of AURKA inhibition in MM and PCL, especially in high-risk and treatment-refractory settings. Here, AURKA is linked to Miyoshi myopathy.